a The Department of Hematology, the First Affiliated Hospital , College of Medicine, Zhejiang University , Hangzhou , China.
b Zhejiang Provincial Key Lab of Hematopoietic Malignancy , Zhejiang University , Hangzhou , China.
Nutr Cancer. 2019;71(4):569-574. doi: 10.1080/01635581.2018.1540718. Epub 2018 Dec 29.
To analyze the clinical characteristics and prognostic value of prognostic nutritional index (PNI) for diffuse large B-cell lymphoma (DLBCL) treated in the rituximab era, baseline clinical and disease characteristics were recorded in our hospital. Concentration of T-helper cell type (Th1/Th2/Th17) cytokine profiles were measured by flow cytometry. DLBCL patients were classified into low and high PNI group based on the cutoff value as previously reported. Clinical features and survivals were compared between high and low group. In all, 114 (37%) out of 309 patients were classified as low PNI group. The low group had lower levels of albumin, hemoglobin and lymphocyte counts, and older age, and high lactate dehydroxygenase (LDH), and high frequencies of advanced stage, poor performance status, B symptoms, extranodal involvement, and higher level of interferon gamma (INF-γ). Low PNI was associated with poor overall survival (OS) in univariate analyses. But these significances did not stand in the paired patients matched by the well-established prognostic factors. In parallel, there was no significance between survival and PNI in the multivariate analyses. PNI was closely correlated with the well-established prognostic factors for DLBCL patients and was not an independent prognostic factor in our study.
为分析利妥昔单抗时代弥漫性大 B 细胞淋巴瘤（DLBCL）患者预后营养指数（PNI）的临床特征和预后价值，我们医院记录了患者的基线临床和疾病特征。通过流式细胞术测定 T 辅助细胞类型（Th1/Th2/Th17）细胞因子谱的浓度。根据既往报道的截断值，将 DLBCL 患者分为低 PNI 组和高 PNI 组。比较两组间的临床特征和生存情况。在 309 例患者中，有 114 例（37%）被归类为低 PNI 组。低 PNI 组白蛋白、血红蛋白和淋巴细胞计数较低，年龄较大，乳酸脱氢酶（LDH）较高，晚期疾病、较差的体能状态、B 症状、结外受累和较高的干扰素 γ（INF-γ）水平更为常见。单因素分析显示，低 PNI 与总生存（OS）不良相关。但这些差异在经明确预后因素配对的患者中并不显著。同时，多因素分析中 PNI 与生存之间也无显著相关性。PNI 与 DLBCL 患者明确的预后因素密切相关，但在本研究中并非独立的预后因素。
